Genetic Factors and the Risk of Periodontitis Development: Findings from a Systematic Review Composed of 13 Studies of Meta-Analysis with 71,531 Participants

Table 1

Main characteristics and results of the studies in meta-analysis published in the period from 2012 to 2016 and included in systematic search.

Med	Author and reference	Year		Polymorphisms	Cases/controls	OR (IC 95%, )	Periodontitis classification
IL-1A	Wang et al. [18]	2014	19	−889 C/T	1,266/2,134	1.00 (0.88–1.14, P = 0.98)	Aggressive
	Silva et al. [15]	2017	23	−889 C/T	2,174/1,756	1.22 (1.09–1.36, P < 0.0004)	Chronic
IL-1B	Zeng et al. [19]	2015	19	−511 C/T	2,173/3,900	1.03 (0.72–1.46, P = 0.88)	Chronic
	Chen et al. [20]	2015	25	+3954 C/T	1,594/2,483	0.99 (0.79–1.23, P = 0.91)	Aggressive
	Ma et al. [21]	2015	20	+3954 C/T	1,656/1,498	1.60 (1.06–2.42, P = 0.02)	Chronic
IL-4	Yan et al. [17]	2015	12; 7; 4	−590 C/T; −33 C/T; 70 pb	1,220/2,039; 715/967; 426/506	1.20 (0.78–1.85, P = 0.42); 0.97 (0.60–1.58, P = 0.91); 1.26 (0.76–2.11, P = 0.37)	Aggressive; Chronic
IL-6	Song et al. [22]	2013	16; 10	−174 G/C; −572 G/C	1,887/1,490; 1,436/998	1.18 (0.91–1.55, P = 0.20); 1.52 (1.15–2.00, P = 0.003)	Aggressive; Chronic
IL-8	Chen et al. [23]	2015	11; 3	−251 A/T; −845 T/C	1,555/2,130; 678/525	0.89 (0.70–1.12, P < 0.001); 1.41 (0.99–2.01, P = 0.40)	Aggressive; Chronic
IL-10	Zhong et al. [24]	2012	5; 7; 6	−1082 A/G; −819 C/T; −592 C/A	1,105/976; 749/603; 673/587	0.96 (0.73–1.26, P = 0.77); 1.13 (0.96–1.33, P = 0.16); 1.38 (1.04–1.85, P = 0.03)	Aggressive; Chronic
IL-18	Li et al. [25]	2014	3; 3	−607 A/C; −137 G/C	576/458; 576/458	1.86 (1.30–2.65, P = 0.192); 1.66 (1.37–2.02, P = 0.281)	Aggressive; Chronic
FCGR2A; FCGR3A; FCGR3B	Song and Lee [10]	2013	7; 6; 1; 3; 3; 3	R131H; F158V; NA1/NA2	1,626/1,496; 7,68/1,256; 178/128; 434 512668/490; 320/364	0.947 (0.814–1.103, P = 0.485); 1.112 (0.918–1.348, P = 0.278); 1.371 (0.810–2.320, P = 0.240); 0.940 (0.673–1.315, P = 0.719); 1.026 (0.806–1.305, P = 0.836); 2.138 (0.956–4.784, P = 0.064)	Chronic; Aggressive; Chronic; Aggressive; Chronic; Aggressive
COX-2	Jiang et al. [8]	2014	5; 2; 3; 1; 2	−765G/C; −1195G/A; 8473 T/C	1,913/2,984; 604/1192; 1,231/2,138; 519/1036; 202/208	1.11 (0.79–1.55, P > 0.005); 1.15 (0.81–1.64, P > 0.005); 0.40 (0.03–5.44, P > 0.005); 1.25 (0.87–1.80, P > 0.005); 0.65 (0.46–0.91, P > 0.005)	Chronic; Aggressive; Chronic; Aggressive; Chronic
MMP-2; MMP-3; MMP-8; MMP-9	Weng et al. [11]	2016	2; 2; 6; 1; 2; 2; 7; 2	−753 C/T; −1171 A5/A6; −799C/T; −1562 C/T	236/234; 171/280; 697/1,530; 37/142; 702/384; 1,96/167; 859/1,186; 191/285	1.28 (1.07–1.54 P > 0.005); 2.01 (0.98–4.11, P > 0.005); 1.44 (1.25–1.66, P < 0.001); 1.54 (0.82–2.89, P = 0.175); 1.28 (1.07–1.54, P > 0.005); 2.01 (0.98–4.11, P > 0.005); 0.49 (0.31–0.77, P = 0.002); 0.93 (0.67–1.29, P = 0.656)	Chronic; Aggressive; Chronic; Aggressive; Chronic; Aggressive; Chronic; Aggressive

Med: inflammatory mediator, IL: interleukins, FGCGR: receptor Fcγ, COX-2: cyclooxygenase 2, MMP: matrix metalloproteinase, N: number of studies included in meta-analysis available, OR: Odds Ratio for the allelic evaluation (mutants allelic × wild allelic comparison), IC: confidence interval, pb: bases pair, and P < 0.05: statistic value significant.